Show simple item record

dc.contributor.authorVeziris, Nicolas
dc.contributor.authorIbrahim, Murad
dc.contributor.authorLounis, Nacer
dc.contributor.authorAndries, Koen
dc.contributor.authorJarlier, Vincent
dc.date.accessioned2018-09-10T18:27:10Z
dc.date.available2018-09-10T18:27:10Z
dc.date.issued2011-03-03
dc.identifier.citationVeziris N, Ibrahim M, Lounis N, Andries K, Jarlier V (2011) Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis. PLoS ONE 6(3): e17556. doi:10.1371/journal.pone.0017556en_US
dc.identifier.issn1932-6203
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/888
dc.description.abstractRationale: The sterilizing activity of the regimen used to treat multidrug resistant tuberculosis (MDR TB) has not been studied in a mouse model. Objective and Methods: Swiss mice were intravenously inoculated with 6 log10 of Mycobacterium tuberculosis (TB) strain H37Rv, treated with second-line drug combinations with or without the diarylquinoline TMC207, and then followed without treatment for 3 more months to determine relapse rates (modified Cornell model). Measurements: Bactericidal efficacy was assessed by quantitative lung colony-forming unit (CFU) counts. Sterilizing efficacy was assessed by measuring bacteriological relapse rates 3 months after the end of treatment. Main Results: The relapse rate observed after 12 months treatment with the WHO recommended MDR TB regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible TB regimen (rifampin, isoniazid and pyrazinamide). When TMC207 was added to this MDR TB regimen, the treatment duration needed to reach the same relapse rate dropped to 6 months. A similar relapse rate was also obtained with a 6-month completely oral regimen including TMC207, moxifloxacin and pyrazinamide but excluding both amikacin and ethionamide. Conclusions: In this murine model the duration of the WHO MDR TB treatment could be reduced to 12 months instead of the recommended 18–24 months. The inclusion of TMC207 in the WHO MDR TB treatment regimen has the potential to further shorten the treatment duration and at the same time to simplify treatment by eliminating the need to include an injectable aminoglycoside.en_US
dc.description.sponsorshipThis work was partly supported by Johnson and Johnson, Beerse, Belgium (128106 euros grant). KA and NL are employees of Tibotec BVBA, a subsidiary of Johnson and Johnson, and participated in the design of the study, analysis of the results and writing of the manuscipt. The laboratory is supported by annual grant EA 1541 from Universite´ Paris 6, Pierre-et-Marie Curie.en_US
dc.language.isoen_USen_US
dc.publisherPublic Library of Scienceen_US
dc.titleSterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosisen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record